ETCAMAH DIN 02570572
Health Canada record
| Active ingredient(s) | CAMIZESTRANT 75 MG |
|---|---|
| Dosage form | Tablet |
| Route | Oral |
| Schedule | PRESCRIPTION RECOMMENDED |
| Class | Human |
| ATC | L02BA05 CAMIZESTRANT |
| Original market date | |
| Current status date | 04-Aug-2026 |
| Source | Health Canada DPD |
Establishment licence of the holder
AstraZeneca Canada Inc. — licence 100421, currently licensed, last inspection rating C (2023-06-12).
No Canadian shortage report is currently matched to this DIN.
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 38047 | 2026-08-04 | New Drug Submission (NDS) |